Oxygenation of the Cerebrum and Cooling During Transcatheter Aortic Valve Implantation (TAVI) Procedures - Part II
Primary Purpose
Aortic Valve Stenosis, Stroke
Status
Unknown status
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
targeted brain cooling (33°C) by RhinoChill device
Placebo - current clinical practice, no cooling
Sponsored by
About this trial
This is an interventional prevention trial for Aortic Valve Stenosis
Eligibility Criteria
Inclusion Criteria:
- pts scheduled for transcatheter aortic valve implantation
Exclusion Criteria:
- pts with pacemaker already implanted
- pts with recent stroke or Transient Ischemic Attacks (TIA) (6months)
- pts with extreme claustrophobia for MRI brain examination
Sites / Locations
- Ziekenhuis Oost-LimburgRecruiting
- Universitair Ziekenhuis
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
targeted brain cooling
no use of targeted brain cooling
Arm Description
In these 15 pts, targeted brain cooling (tympanic temperature of 33°C) will be applied during the TAVI intervention by the use of the RhinoChill device (Benechill Inc, San Diego cA)
In these 15 pts, no cooling techniques will be applied and current clinical practice as to maintenance of normothermia will be followed during these TAVI interventions
Outcomes
Primary Outcome Measures
changes in cerebral oxygen saturation during periods of rapid ventricular pacing and valve implantation
changes in cerebral oxygen saturation during periods of rapid ventricular pacing (RVP) and valve implantation; changes in cerebral oxygen saturation compared to baseline values (of 10min) before periods of RVP (Area Under the Curve will be analysed and compared between cooled end non-cooled patients
Secondary Outcome Measures
composite outcome measure : MRI of the brain before and after TAVI; NSE before and after TAVI; S100-B before and after TAVI; neuropsychological testing before and after TAVI
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01822964
Brief Title
Oxygenation of the Cerebrum and Cooling During Transcatheter Aortic Valve Implantation (TAVI) Procedures - Part II
Study Type
Interventional
2. Study Status
Record Verification Date
March 2013
Overall Recruitment Status
Unknown status
Study Start Date
March 2013 (undefined)
Primary Completion Date
March 2014 (Anticipated)
Study Completion Date
December 2014 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hasselt University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of this study is to assess the possible neuroprotective effects of cooling (targeted cooling of the brain to 33°C) during Transcatheter Aortic Valve Implantation (TAVI) procedures. From start of anesthesia, until final valve implantation, local cooling (by the RhinoChill device) will be applied to the brain. Effect of cooling on cerebral oxygenation, by cerebral oxygen saturation monitoring (NIRS ForeSight technology) during the TAVI procedure will be continuously assessed during native valve manipulation and during final valve deployment (=primary endpoint of he study). As secondary endpoints, neuropsychological testing performed before and after TAVI procedure will assess the effects of the use of cooling during the TAVI procedure. Neuron-specific enolase (NSE) and S100-beta will be analyzed during and up to 72hrs after TAVI to compare the cerebral ischemic damage between cooled and non-cooled patients. And finally, diffusion-weighted MRI of the brain will be performed 5 days before and 5-7 days after TAVI to compare the number and total amount of cerebral ischemic insults between cooled and non-cooled patients. The hypothesis behind this study is that by local cooling of the brain during manipulation of the calcified aorta and aortic valve, the brain might be protected from cerebral ischemic insults.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aortic Valve Stenosis, Stroke
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
30 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
targeted brain cooling
Arm Type
Active Comparator
Arm Description
In these 15 pts, targeted brain cooling (tympanic temperature of 33°C) will be applied during the TAVI intervention by the use of the RhinoChill device (Benechill Inc, San Diego cA)
Arm Title
no use of targeted brain cooling
Arm Type
Placebo Comparator
Arm Description
In these 15 pts, no cooling techniques will be applied and current clinical practice as to maintenance of normothermia will be followed during these TAVI interventions
Intervention Type
Device
Intervention Name(s)
targeted brain cooling (33°C) by RhinoChill device
Intervention Description
targeted brain cooling by Rhinochill device to 33°C tympanic temperature during TAVI procedure. After valve implantation, slow rewarming until 35.5°C
Intervention Type
Device
Intervention Name(s)
Placebo - current clinical practice, no cooling
Primary Outcome Measure Information:
Title
changes in cerebral oxygen saturation during periods of rapid ventricular pacing and valve implantation
Description
changes in cerebral oxygen saturation during periods of rapid ventricular pacing (RVP) and valve implantation; changes in cerebral oxygen saturation compared to baseline values (of 10min) before periods of RVP (Area Under the Curve will be analysed and compared between cooled end non-cooled patients
Time Frame
during TAVI procedure
Secondary Outcome Measure Information:
Title
composite outcome measure : MRI of the brain before and after TAVI; NSE before and after TAVI; S100-B before and after TAVI; neuropsychological testing before and after TAVI
Time Frame
one year
Other Pre-specified Outcome Measures:
Title
composite outcome measure : General Clinical Endpoints (as referring to the Valval Academic Research Consortium (VARC) - 2 recommendations)
Description
These clinical endpoints include : all-cause mortality; myocardial infarction; stroke & TIA; bleeding complication; acute kidney injury; vascular complications; conductance disturbances and arrhythmias; other TAVI-related complications; valvular function and quality of life
Time Frame
one year
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
pts scheduled for transcatheter aortic valve implantation
Exclusion Criteria:
pts with pacemaker already implanted
pts with recent stroke or Transient Ischemic Attacks (TIA) (6months)
pts with extreme claustrophobia for MRI brain examination
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Cathy S De Deyne, MD, PhD
Phone
003289325296
Email
cathy.dedeyne@ZOL.be
First Name & Middle Initial & Last Name or Official Title & Degree
Jo A Dens, Md, PhD
Phone
003289327088
Email
jo.dens@ZOL.be
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cathy S De Deyne, Md, PhD
Organizational Affiliation
University Hasselt / Ziekenhuis Oost-Limburg Genk (Belgium)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ziekenhuis Oost-Limburg
City
Genk
ZIP/Postal Code
3600
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cathy S De Deyne, MD, PhD
Phone
003289325296
Email
cathy.dedeyne@ZOL.be
First Name & Middle Initial & Last Name & Degree
Jo A Dens, MD, PhD
Phone
003289327088
Email
jo.dens@ZOL.be
First Name & Middle Initial & Last Name & Degree
Jo A Dens, MD, PhD
Facility Name
Universitair Ziekenhuis
City
Leuven
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christophe Dubois, MD,PhD
Email
christophe.dubois@uzleuven.be
First Name & Middle Initial & Last Name & Degree
Christophe Dubois, MD,PhD
12. IPD Sharing Statement
Citations:
Citation
1. Vahanian A, Alfieri O, Al-Attar N, Antunes M, Bax J, Cornier B, Cribier A, De Jaegere P, Fournial G, Kappetein AP et al. Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European association of cardio-thoracic surgery (EACTS- and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eurointervention 2008;4:193-199 2. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Eng J Med 2010;363:1597-1607 3. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tizcu EM, Webb JG, Fontana GP, Makkar RR et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Eng J Med 2011;364:2187-2198 4. Grube E, Naber C, Abizaid A, Sousa E, Mendiz O, Lemos P et al. Feasibility of transcatheter aortic valve implantation withoutn balloon pre-dilatation. JACC Cardiovasc Interv 2011;4:751-757 5. Bagur R, Rodes-Cabau J, Doyle D, De Larochelière R, Villeneuve J, Bertrand OF et al. Transcatheter aortic valve implantation with
Results Reference
background
Learn more about this trial
Oxygenation of the Cerebrum and Cooling During Transcatheter Aortic Valve Implantation (TAVI) Procedures - Part II
We'll reach out to this number within 24 hrs